Supporting Information

Potthoff et al.



Fig. S1. (*A*) Plasma glucagon concentrations in wild-type (WT) and FGF21-transgenic (FGF21-TG) male mice ($n = 7–8$ per group). (*B*) Hepatic *Pgc1β* mRNA levels in fed WT and FGF21-TG male mice ($n = 5$ per group).



Fig. S2. *Fgf21* genomic structure, targeting vector, and targeted allele. *loxP* sites were inserted upstream of exon 1 and downstream of exon 3. Positions of RT-PCR primers for exons 1–3 (E1, E2R, E2F, and E3) are shown as arrows.



Fig. S3. (*A*) Western blot analysis for phosphorylated Foxo1, phosphorylated CREB, and total and phosphorylated TORC2 in liver lysates prepared from mice 15 min after injection of either vehicle or FGF21 (0.75 μg/g). β-Actin served as a loading control. (*B*) Gluconeogenic gene expression was analyzed in livers isolated from male mice perfused for 1 hr with media containing vehicle or FGF21 (40 ng/ml) ($n = 4$ per group). (*C* and *D*) *Pgc1*α mRNA levels were analyzed in mouse (*C*) or rat (*D*) hepatocytes treated with vehicle or recombinant FGF21 (100 ng/ml) for the indicated times.